Monday, November 6, 2017
- 9:00AM-11:00AM
-
Abstract Number: 1101
Systematic Physician Assessment Beyond Inflammation in Routine Rheumatology Care Using Visual Analog Scale Scores for Inflammation, Damage, and Distress to Document Patient Status and Support Clinical Decisions: Analysis of Inter-Rater Reliability
Measures and Measurement of Healthcare Quality Poster I- 9:00AM-11:00AM
-
Abstract Number: 1052
Systematic Review of Modelling Approaches and Quality for the Cost Effectiveness of sequential Targeted Therapy in Patients with Rheumatoid Arthritis That Show an Inadequate Response to at Least One Tumor Necrosis Factor Alpha Inhibitor
Health Services Research Poster II: Osteoarthritis and Rheumatoid Arthritis- 9:00AM-11:00AM
-
Abstract Number: 1166
Systemic Degos Disease: Long Term Survival on Combined Therapy with Eculizumab and Treprostinil
Miscellaneous Rheumatic and Inflammatory Diseases Poster I- 9:00AM-11:00AM
-
Abstract Number: 1433
Tailoring Second-Line Biologic Therapy in Rheumatoid Arthritis: New Findings on the Usefulness of Antibody Status to Optimise Drug Selection
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster II: Prognostic Factors, Imaging and Miscellaneous Reports- 9:00AM-11:00AM
-
Abstract Number: 1444
Targeted Therapeutic Delivery to Cartilage with Knottin Proteins
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster II: Prognostic Factors, Imaging and Miscellaneous Reports- 9:00AM-11:00AM
-
Abstract Number: 1319
TAS05567 Is a Novel Potent and Selective Spleen Tyrosine Kinase Inhibitor That Attenuates Disease Severity in Animal Models of Autoimmune Diseases
Rheumatoid Arthritis – Animal Models Poster II- 9:00AM-11:00AM
-
Abstract Number: 1320
TAS5315, a Novel Bruton’s Tyrosine Kinase Inhibitor, Ameliorates Inflammation and Bone Erosion in Murine Model for Rheumatoid Arthritis
Rheumatoid Arthritis – Animal Models Poster II- 9:00AM-11:00AM
-
Abstract Number: 1051
Telemedicine for Rheumatoid Arthritis in the Alaska Native Population
Health Services Research Poster II: Osteoarthritis and Rheumatoid Arthritis- 9:00AM-11:00AM
-
Abstract Number: 1609
Telomere Length and Coronary Artery Atherosclerosis in Patients with Systemic Lupus Erythematosus
Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster II: Damage and Comorbidities- 9:00AM-11:00AM
-
Abstract Number: 1345
Tender Joints Have Low Associations with Patient’s Evaluation of Joint Pain and Ultrasound Findings Explored at Joint Level in Patients with Rheumatoid Arthritis
Rheumatoid Arthritis – Clinical Aspects Poster II: Pathophysiology, Autoantibodies, and Disease Activity Measures- 9:00AM-11:00AM
-
Abstract Number: 1386
Tenosynovitis in the Forefoot at Disease Presentation Is Specific for RA: Results from a Cross-Sectional MRI Study in Early Arthritis
Rheumatoid Arthritis – Clinical Aspects Poster II: Pathophysiology, Autoantibodies, and Disease Activity Measures- 9:00AM-11:00AM
-
Abstract Number: 1720
TGF-ß-Induced Tissue Fibrosis in TBRIcaCol1Cre Transgenic Mice Is Abrogated By the Second Generation Tyrosine Kinase Inhibitor SKI-606 (Bosutinib)
Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics Poster II- 9:00AM-11:00AM
-
Abstract Number: 1076
TGF-β1 Induces AXL in Murine and Human Synovium and Protects Ankle Joints, but Not Knee Joints, during Murine Inflammatory Arthritis
Innate Immunity and Rheumatic Disease Poster II- 9:00AM-11:00AM
-
Abstract Number: 1716
TGFβ-Dependent Upregulation of XIAP Fosters Fibroblast Activation and Tissue Fibrosis By Promoting Canonical Wnt Signaling